The Company aims to begin its first in-human study in Israel in Q3 and in U.S. study is intended to be a precursor to the eventual pivotal trial for FDA clearance.

Klonoff, Chair of the Company’s Scientific Advisory Board and Medical Director of the Diabetes Research Institute of Mills-Peninsula Medical Center. The initial results from this study will drive a follow-up multi-center study in the United States, led by Dr.

The Company has recently received Ethics Committee and clinical center approvals to conduct this study at the Rabin Medical Center in Israel. Initial data collected indicates that the Gen 2 system may achieve an accuracy comparable to invasive Continuous Glucose Monitors (CGM’s) currently available in the market when conducting the upcoming first in-human clinical study.

During this in-house testing, the Company achieved better than expected accuracy and performance. The completion of bench testing and analyses of the Gen 2 clinical prototype system was followed by simulated use testing. In addition, human factors testing of the mobile app has been completed through simulated use in focus groups and by conducting a rigorous external design review for system architecture, stability, and cybersecurity. This process included testing of multiple iterations of electronics, ear clip, and mobile app with cloud-based software. In early Q2 the Company completed lab testing of its Gen 2 clinical prototype system. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a non-invasive device and digital health platform for measuring glucose levels in people with Type 2 diabetes and prediabetes, announced today that it has provided an update on the development of GlucoTrack 2.0 (or “Gen 2”). Rutherford, NJ and Or Yehuda, Israel, J(GLOBE NEWSWIRE) - GlucoTrack, Inc.

Download gluco d cost